In a unanimous decision, the Supreme Court ruled Thursday morning that human genes are not patentable. The case centered around Myriad Genetics, the holder of patents on two genes, BRCA 1 and BRCA 2. Some mutations of these genes are associated with an increased risk of breast and ovarian cancer. For women with a strong family history of these cancers, the only place they could be tested was Myriad Genetics, which sometimes charged more than $3,000 for the test. Breast Cancer Action, an advocacy group based in San Francisco, was a plaintiff in the case and executive director Karuna Jagger sounded jubilant in a phone call Thursday morning.